NO20063501L - Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese - Google Patents
Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres synteseInfo
- Publication number
- NO20063501L NO20063501L NO20063501A NO20063501A NO20063501L NO 20063501 L NO20063501 L NO 20063501L NO 20063501 A NO20063501 A NO 20063501A NO 20063501 A NO20063501 A NO 20063501A NO 20063501 L NO20063501 L NO 20063501L
- Authority
- NO
- Norway
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- receptor tyrosine
- synthesis
- intermediates
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 3
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- -1 4-substituted quinoline compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53732904P | 2004-01-16 | 2004-01-16 | |
| PCT/US2005/001384 WO2005070890A2 (en) | 2004-01-16 | 2005-01-14 | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063501L true NO20063501L (no) | 2006-09-28 |
Family
ID=34807094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063501A NO20063501L (no) | 2004-01-16 | 2006-08-01 | Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7432377B2 (uk) |
| EP (1) | EP1711467A2 (uk) |
| KR (1) | KR20060123545A (uk) |
| CN (1) | CN1930128A (uk) |
| AR (1) | AR047424A1 (uk) |
| AU (1) | AU2005206541A1 (uk) |
| BR (1) | BRPI0520812A2 (uk) |
| CA (1) | CA2553729A1 (uk) |
| CR (1) | CR8530A (uk) |
| EC (1) | ECSP066773A (uk) |
| GT (1) | GT200500008A (uk) |
| MY (1) | MY136959A (uk) |
| NO (1) | NO20063501L (uk) |
| PA (1) | PA8621501A1 (uk) |
| PE (1) | PE20050896A1 (uk) |
| RU (1) | RU2006127414A (uk) |
| SG (1) | SG149817A1 (uk) |
| TW (1) | TW200526219A (uk) |
| UA (1) | UA85698C2 (uk) |
| WO (1) | WO2005070890A2 (uk) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500008A (es) * | 2004-01-16 | 2005-08-16 | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos | |
| CN101203494A (zh) * | 2005-05-25 | 2008-06-18 | 惠氏公司 | 合成经取代3-氰基喹啉和其中间物的方法 |
| CA2608394A1 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of preparing 3-cyano-quinolines and intermediates made thereby |
| WO2006127203A2 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing 6-alkylaminoquinoline derivatives |
| TW200808728A (en) * | 2006-05-23 | 2008-02-16 | Wyeth Corp | Method of preparing 4-halogenated quinoline intermediates |
| US8093246B2 (en) * | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8063220B2 (en) | 2007-06-22 | 2011-11-22 | Richter Gedeon Nyrt. | Sulfonyl-quinoline derivatives |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CA2743449C (en) | 2008-11-12 | 2016-10-18 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| MX336875B (es) | 2010-08-10 | 2016-02-04 | Celgene Avilomics Res Inc | Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk). |
| WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
| EP2635284B1 (en) | 2010-11-01 | 2019-12-18 | Celgene CAR LLC | Heterocyclic compounds and uses thereof |
| WO2012064706A1 (en) | 2010-11-10 | 2012-05-18 | Avila Therapeutics, Inc. | Mutant-selective egfr inhibitors and uses thereof |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
| CA2866852C (en) | 2012-03-15 | 2020-12-29 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
| BR112014022790B1 (pt) | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| EP3188642B1 (en) * | 2014-09-01 | 2018-05-30 | Electrolux Appliances Aktiebolag | Support assembly |
| JP6740354B2 (ja) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
| CN105503720B (zh) * | 2015-12-31 | 2018-07-03 | 重庆威鹏药业有限公司 | 来那替尼中间体的制备方法 |
| CN107501175A (zh) * | 2017-07-25 | 2017-12-22 | 广州大学 | 一种喹啉衍生物的合成方法 |
| CN107501174A (zh) * | 2017-07-25 | 2017-12-22 | 广州大学 | 一种喹啉衍生物的合成方法 |
| CN107417612A (zh) * | 2017-07-25 | 2017-12-01 | 广州大学 | 一种喹啉衍生物的合成方法 |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT4003532T (lt) | 2019-07-24 | 2024-11-11 | Constellation Pharmaceuticals, Inc. | 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos |
| KR102713340B1 (ko) * | 2022-11-08 | 2024-10-02 | 경희대학교 산학협력단 | 고리화첨가 반응과 고리축소 반응의 연속 반응을 이용한 피롤로[1,2-a]퀴놀린의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| SI0991628T1 (en) | 1997-05-28 | 2005-06-30 | Aventis Pharmaceuticals Inc | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
| US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| IL142092A0 (en) | 1998-09-29 | 2002-03-10 | American Cyanamid Co | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| WO2001055116A2 (en) | 2000-01-28 | 2001-08-02 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| EP1337513A1 (en) * | 2000-11-02 | 2003-08-27 | AstraZeneca AB | 4-substituted quinolines as antitumor agents |
| UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| JP2005536462A (ja) * | 2002-04-30 | 2005-12-02 | ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド | カスパーゼ−３阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物 |
| CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
| US7365203B2 (en) * | 2003-09-15 | 2008-04-29 | Wyeth | Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile |
| GT200500008A (es) | 2004-01-16 | 2005-08-16 | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos | |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
-
2005
- 2005-01-14 GT GT200500008A patent/GT200500008A/es unknown
- 2005-01-14 CA CA002553729A patent/CA2553729A1/en not_active Abandoned
- 2005-01-14 EP EP05711511A patent/EP1711467A2/en not_active Withdrawn
- 2005-01-14 KR KR1020067016319A patent/KR20060123545A/ko not_active Withdrawn
- 2005-01-14 PA PA20058621501A patent/PA8621501A1/es unknown
- 2005-01-14 UA UAA200609099A patent/UA85698C2/uk unknown
- 2005-01-14 US US11/036,408 patent/US7432377B2/en not_active Expired - Fee Related
- 2005-01-14 CN CNA2005800077483A patent/CN1930128A/zh active Pending
- 2005-01-14 AU AU2005206541A patent/AU2005206541A1/en not_active Withdrawn
- 2005-01-14 BR BRPI0520812-2A patent/BRPI0520812A2/pt not_active IP Right Cessation
- 2005-01-14 WO PCT/US2005/001384 patent/WO2005070890A2/en not_active Ceased
- 2005-01-14 SG SG200900078-7A patent/SG149817A1/en unknown
- 2005-01-14 TW TW094101148A patent/TW200526219A/zh unknown
- 2005-01-14 RU RU2006127414/04A patent/RU2006127414A/ru not_active Application Discontinuation
- 2005-01-15 MY MYPI20050166A patent/MY136959A/en unknown
- 2005-01-17 PE PE2005000069A patent/PE20050896A1/es not_active Application Discontinuation
- 2005-01-17 AR ARP050100169A patent/AR047424A1/es unknown
-
2006
- 2006-07-24 CR CR8530A patent/CR8530A/es not_active Application Discontinuation
- 2006-08-01 NO NO20063501A patent/NO20063501L/no not_active Application Discontinuation
- 2006-08-16 EC EC2006006773A patent/ECSP066773A/es unknown
-
2008
- 2008-08-28 US US12/200,120 patent/US20090030197A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PA8621501A1 (es) | 2005-08-10 |
| AU2005206541A1 (en) | 2005-08-04 |
| CN1930128A (zh) | 2007-03-14 |
| AR047424A1 (es) | 2006-01-18 |
| CA2553729A1 (en) | 2005-08-04 |
| WO2005070890A3 (en) | 2005-11-03 |
| CR8530A (es) | 2008-09-23 |
| ECSP066773A (es) | 2006-11-16 |
| MY136959A (en) | 2008-12-31 |
| EP1711467A2 (en) | 2006-10-18 |
| US20090030197A1 (en) | 2009-01-29 |
| WO2005070890A2 (en) | 2005-08-04 |
| SG149817A1 (en) | 2009-02-27 |
| BRPI0520812A2 (pt) | 2009-10-06 |
| US20050159446A1 (en) | 2005-07-21 |
| UA85698C2 (uk) | 2009-02-25 |
| KR20060123545A (ko) | 2006-12-01 |
| GT200500008A (es) | 2005-08-16 |
| TW200526219A (en) | 2005-08-16 |
| RU2006127414A (ru) | 2008-02-27 |
| US7432377B2 (en) | 2008-10-07 |
| PE20050896A1 (es) | 2005-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20063501L (no) | Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese | |
| NO20071242L (no) | Triazolpyridinylsulfanylderivater som P38-MAP-kinaseinhibitorer | |
| NO20071619L (no) | Fremgangsmate for fremstilling av indazol forbindelse | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| NO20081001L (no) | Derivater av karboksamid som antagonister for muskarinisk reseptor | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
| NO20063780L (no) | Fremgangsmate for fremstilling av 2-aminitiazol-5-aromatisk karboksamid som kinase inhibitorer. | |
| NO20073663L (no) | Tiazol-4-karboksamid-derivater som mGluR5 antagonister | |
| NO20082482L (no) | Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer | |
| NO20075624L (no) | Nye histamin H3-reseptorligander og deres terapeutiske anvendelser | |
| NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
| SE0400284D0 (sv) | Novel compounds | |
| WO2006050109A3 (en) | Novel kinase inhibitors | |
| NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
| NO20073208L (no) | 4-fenylsubstituerte tetrahydrotsokindiner og anvendelse derav til a blokkere gjenopptak av norepinefrin, dopamin og serotonin | |
| NO20076145L (no) | Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav | |
| EA200801608A1 (ru) | Производные бензимидазолонкарбоновой кислоты | |
| NO20073170L (no) | Kaspaseinhibitorer og anvendelse derav | |
| NO20081621L (no) | Tetrahydrokinoliner, syntese og intermediater | |
| EA201071269A1 (ru) | 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| EA200600061A1 (ru) | Бензамиды 4-(аминометил) пиперидина как 5нт-антагонисты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |